Sustained effects of low dose infliximab in combination with methotrexate in the management of chronic recalcitrant psoriasis

Dermatology Online Journal

Volumn 11, Issue 3, 2005, Pages

  Zargari, Omid ^a  

^a GUILAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOSPORIN; ETRETIN; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; RETINOID; SALAZOSULFAPYRIDINE;

ABSENCE OF SIDE EFFECTS; ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG EFFECT; FEMALE; HUMAN; INJECTION SITE REACTION; LIVER BIOPSY; LOW DRUG DOSE; PSORIASIS; PUVA;

EID: 29844445864     PISSN: 10872108     EISSN: 10872108     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Lebwohl M, Menter A, Koo J, Feldman SR. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol 2004;50:416-30
2. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RDR. Elevated tumor necrosis factor-alpha biological activity in psoriatic skin lesions. Clin Exp Immunol 1994;96:146-51
3. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal anti-body cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995;7:251-9
4. Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor α (TNF- α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 2000;42:829-30
5. Chaudhari U, Romano P, Mulcahy L, Dooley L, Baker D, Gottlieb A. efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 2001;357:1842-7
6. Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor α, infliximab. J Am Acad Dermatol 2002;46:886-91
7. Gottlieb AB, Chaudhari U, Mulcahy L, Li S, Dooley L, Baker D. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol 2003;48:829-35
8. Vincek V, Jacob SE, Nassiri M, Herbert LM, Nadji M, Kerdel FA. Infliximab monotherapy in psoriasis: A case of rapid clinical and histological response. Int J Dermatol 2004;43:303-8
9. Gottlieb AB. Infliximab for psoriasis. J Am Acad Dermatol 2003;49:S112-17
10. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: antitumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 2000;343:1594-602
11. Baert F, Noman M, Vermeire S, Van Assche G, DÕ Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in CrhonÕs disease. N Engl J Med 2003;348:601-8
12. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104